Annovis BioAdvance News Portfolio News

Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease

By WebmasterJanuary 25, 2023November 1st, 2024No Comments

Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease

Strong enrollment in Phase 3 trial demonstrates continued execution

Interim analysis expected in 2Q 2023

Previous PostStrados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study
Next PostiVIEW announces Completion of First Patient Treatment in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis